Sydney M Crago

This acquisition will include Adverum’s lead candidate, Ixo-vec, a gene therapy treatment for wet AMD.

The results presented at 2025 European Society of Medical Oncology meeting support neoadjuvant darovasertib as a potential treatment to delay or prevent progression of the disease.

Topcon Healthcare enhances its AI capabilities by acquiring Toku, Inc., aiming to revolutionize eye care with advanced predictive health insights.

The AAO 2025 meeting offered a platform for companies to showcase their latest technologies to advance ophthalmic patient care.

New research highlights iron dysregulation's role in dry AMD, suggesting transferrin as a promising treatment to slow disease progression.

The 24-month results of this first-in-human trial supports the potential long-term outcomes of this system to lower IOP.

Catch up on news you may have missed at the meeting in Orlando, like the effects of GLP-1 drugs on eye health and a potential sign of cardiovascular disease.

Sunir J. Garg, MD, explores the nuances of endophthalmitis, distinguishing between infectious and non-infectious responses for effective patient management.

Research reveals significant vision improvements and extended treatment intervals with aflibercept 8 mg for age-related macular degeneration and diabetic edema patients.

Phase 2 STARLIGHT study participants, particularly those with the macular phenotype, experienced meaningful gains in visual acuity at 48 weeks.

Bedrood describes improved visualization of the ciliary body, efficient setup, and favorable postoperative outcomes.

Innovations in selective laser trabeculoplasty and laser cyclophotocoagulation focus on procedural efficiency, patient comfort, and evolving first-line treatment strategies.

The annual scientific meeting of the American Academy of Ophthalmology highlighted research in retina, refractive surgery, and accessible care.

John P. Berdahl, MD, discusses advanced lens options for patients with pseudoexfoliation, highlighting considerations for successful longterm outcomes.

In the Phase 2 TEASE 2 trial, gildeuretinol was well tolerated and showed promising trends in slowing ellipsoid zone loss and preserving low-luminance visual acuity in patients with Stargardt disease.

A new study reveals enhanced safety and efficacy in epi-on cross-linking for keratoconus, utilizing oxygen-rich boost goggles during treatment.

The second day of the annual scientific meeting of the American Academy of Ophthalmology highlighted advancements in AI, surgery technology, and money-saving solutions.

Data suggests the candidate can reduce the number of injections and treatment burden for patients

The first day of the American Academy of Ophthalmology meeting in Orlando, Florida featured presentations centered on eye injuries and data insights.

Durga Borkar, MD, MMCi, explores real-world treatment patterns and safety of avacincaptad pegol for geographic atrophy, revealing critical insights for patient care.

Learn how the YOURS Committee empowers young retina specialists through engaging educational initiatives, networking opportunities, and exam preparation resources.

Holz discusses advancements in retinal disease treatments at the EURETINA meeting, featuring gene therapy and innovative implants to enhance patient care.

As of October 1, 2025, the Centers for Medicare & Medicaid Services (CMS) has assigned a permanent J-code (J3403) to revakinagene taroretcel-lwey.